Liver Function Tests (LFTs) Interpretation Guide for Medical Students

Added:

Limitations of Static Pattern-Based LFT Interpretation

While mastering traditional 'hepatocellular versus cholestatic' patterns is a staple of medical education, modern hepatologists highlight significant limitations to this approach. First, the term 'Liver Function Tests' is a misnomer; enzymes like AST, ALT, and alkaline phosphatase indicate cellular damage or biliary obstruction rather than actual synthetic or metabolic liver function, which is better measured by PT/INR, albumin, and bilirubin. Second, rigid pattern-based classification oversimplifies clinical reality, as mixed patterns are highly common and can lead to premature diagnostic closure. Furthermore, static enzyme levels are notoriously insensitive for detecting chronic, progressive conditions; patients with advanced metabolic dysfunction-associated steatotic liver disease (MASLD) or compensated cirrhosis often present with completely normal transaminases. Consequently, contemporary clinical guidance advocates for shifting focus away from sole reliance on traditional LFT ratios and toward the early integration of non-invasive fibrosis assessment tools, such as the FIB-4 index and transient elastography (FibroScan), which offer superior prognostic value.

Basic anatomy and histology of the liver, including the structure of hepatocytes, the biliary tree, and hepatic lobules.
The physiological functions of the liver, specifically protein synthesis (albumin, coagulation factors) and bilirubin metabolism (conjugation and excretion).
Identification of key biochemical markers associated with the liver, such as aminotransferases (ALT, AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin.
Fundamental pathophysiology of cell injury versus biliary obstruction (cellular necrosis vs. cholestasis).
Interpretation of secondary diagnostic tests, including viral hepatitis serologies, autoimmune markers (ANA, ASMA), and iron studies for hereditary hemochromatosis.
Evaluation and clinical application of liver disease severity scoring systems, such as the Child-Pugh score and the Model for End-Stage Liver Disease (MELD).
Correlation of LFT patterns with abdominal imaging findings (ultrasound, CT, MRCP) and non-invasive fibrosis assessments (FibroScan).
Management and treatment protocols for specific conditions diagnosed via LFTs, such as Drug-Induced Liver Injury (DILI), Non-Alcoholic Fatty Liver Disease (NAFLD), and acute liver failure.
386.9K views7.4Klikes26:45@StrongMedOriginal Release: 2014-10-08

Liver Function Tests (LFTs) evaluate liver damage, biliary system integrity, and synthetic function through key markers: AST and ALT (hepatocellular enzymes), ALP and GGT (biliary enzymes), albumin and INR (synthetic function), and bilirubin (conjugated/unconjugated). AST and ALT are transaminases where ALT is more liver-specific than AST; elevated levels indicate hepatocellular injury (hepatitis, cirrhosis, drug toxicity, fatty liver) or biliary disease. ALP and GGT help distinguish cholestatic disease (bile flow obstruction) from hepatocellular disease, with GGT also indicating alcohol abuse. Albumin reflects hepatic synthetic capacity, while INR assesses clotting factor production. Bilirubin metabolism reveals hemolysis (unconjugated elevation) or biliary obstruction (conjugated elevation). Five diagnostic patterns emerge: hepatocellular (AST/ALT elevated), cholestatic (ALP/GGT elevated), isolated hyperbilirubinemia, isolated synthetic dysfunction, and cirrhotic (combined derangements of bilirubin, albumin, and INR).